{
    "nct_id": "NCT04793958",
    "official_title": "A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy",
    "inclusion_criteria": "* Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.\n* Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).\n* Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).\n* Active brain metastasis",
    "miscellaneous_criteria": ""
}